Trials / Sponsors / Nanoscope Therapeutics Inc.

Nanoscope Therapeutics Inc.

Industry · 8 registered clinical trials — 2 currently recruiting.

Status	Trial	Phase	Started
Recruiting	A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT Macular Degeneration, Geographic Atrophy, Stargardt Disease	—	2025-01-28
Active Not Recruiting	Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study Retinitis Pigmentosa, Retinitis, Retinal Diseases	—	2023-12-08
Active Not Recruiting	Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study Stargardt Disease	—	2023-10-19
Enrolling By Invitation	A Long-Term Follow-Up Study in Subjects Who Received vMCO-I Administered Via Intravitreal Injection Retinitis Pigmentosa, Retinal Disease, Retinal Degeneration	—	2023-07-14
Completed	Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT Retinitis Pigmentosa, Retinal Dystrophy	—	2023-04-25
Completed	Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargar Stargardt Disease	Phase 2	2022-07-05
Completed	Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE] Retinitis Pigmentosa, Retinitis, Retinal Diseases	Phase 2	2021-07-13
Completed	Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa, Retinal Diseases, Retinal Degeneration	Phase 1 / Phase 2	2019-10-23